ArticleESC heart failure2025
Identification, characterisation and outcomes of pre-atrial fibrillation in heart failure with reduced ejection fraction.
Article in ESC heart failure, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Impact of rate-pressure product correction of myocardial blood flow on the prognostic relevance in patients with heart failure.European heart journal. Cardiovascular Imaging · 2026Article
- Stratifying prognosis in heart failure patients with reduced ejection fraction and atrial cardiomyopathy.ESC heart failure · 2026Article
- Cardiac magnetic resonance imaging-derived atrial fibrosis in patients with pre-atrial fibrillation.Open heart · 2025Article
- Identification, characterisation and outcomes of pre-atrial fibrillation in heart failure with reduced ejection fraction.ESC heart failure · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aimsAtrial fibrillation (AF) in heart failure with reduced ejection fraction (HFrEF) has prognostic implications. Using a machine learning algorithm (FIND-AF), we aimed to explore clinical events and the cardiac magnetic resonance (CMR) characteristics of the pre-AF phenotype in HFrEF. METHODS AND
resultsA cohort of individuals aged ≥18 years with HFrEF without AF from the MATCH 1 and MATCH 2 studies (2018-2024) stratified by FIND-AF score. All received cardiac magnetic resonance using Cvi42 software for volumetric and T1/T2. The primary outcome was time to a composite of MACE inclusive of heart failure hospitalisation, myocardial infarction, stroke and all-cause mortality. Secondary outcomes included the association between CMR findings and FIND-AF score. Of 385 patients [mean age 61.7 (12.6) years, 39.0% women] with a median 2.5 years follow-up, the primary outcome occurred in 58 (30.2%) patients in the high FIND-AF risk group and 23 (11.9%) in the low FIND-AF risk group (hazard ratio 3.25, 95% CI 2.00-5.28, P < 0.001). Higher FIND-AF score was associated with higher indexed left ventricular mass (β = 4.7, 95% CI 0.5-8.9), indexed left atrial volume (β = 5.9, 95% CI 2.2-9.6), higher indexed left ventricular end-diastolic volume (β = 9.55, 95% CI 1.37-17.74, P = 0.022), native T1 signal (β = 18.0, 95% CI 7.0-29.1) and extracellular volume (β = 1.6, 95% CI 0.6-2.5).
conclusionsA pre-AF HFrEF subgroup with distinct CMR characteristics and poor prognosis may be identified, potentially guiding interventions to reduce clinical events.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.